Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pindolol
Drug ID BADD_D01776
Description Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension.[L32353] Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia.[A231059] Research into pindolol's use in the treatment of hypertension began in the early 1970s.[A231064] Pindolol was granted FDA approval on 3 September 1982.[L32348]
Indications and Usage Pindolol is indicated in the management of hypertension.[L32353] In Canada, it is also indicated in the prophylaxis of angina.[L32388]
Marketing Status approved; investigational
ATC Code C07AA03
DrugBank ID DB00960
KEGG ID D00513
MeSH ID D010869
PubChem ID 4828
TTD Drug ID D0F2PO
NDC Product Code 72789-099; 72789-294; 49169-0006; 29033-028; 57664-655; 72789-293; 0378-0127; 76385-132; 62559-560; 70710-1063; 64330-109; 70771-1134; 70771-1135; 76385-131; 57664-656; 62559-561; 0378-0052; 72789-100; 29033-029; 70710-1064; 10135-743; 10135-744
UNII BJ4HF6IU1D
Synonyms Pindolol | Prindolol | Visken | LB-46 | LB 46 | LB46
Chemical Information
Molecular Formula C14H20N2O2
CAS Registry Number 13523-86-9
SMILES CC(C)NCC(COC1=CC=CC2=C1C=CN2)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gastrointestinal pain07.01.05.005--
Hallucination19.10.04.003--
Headache17.14.01.001--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypotension24.06.03.002--
Insomnia19.02.01.002; 17.15.03.002--
Intermittent claudication24.04.03.001--Not Available
Keratitis06.04.02.002--
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Loss of consciousness17.02.04.004--Not Available
Menopausal symptoms21.02.02.002--Not Available
Muscle spasms15.05.03.004--
Myalgia15.05.02.001--
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Nightmare19.02.03.003--Not Available
Oculomucocutaneous syndrome23.03.01.022; 07.05.01.010; 06.04.05.014--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Pain08.01.08.004--
Palpitations02.11.04.012--
Paraesthesia23.03.03.094; 17.02.06.005--
Peripheral coldness24.04.03.006; 08.01.09.010; 23.06.04.008--Not Available
Pollakiuria20.02.02.007--
Pruritus23.03.12.001--
Psoriasis23.03.14.002; 10.02.01.036--Not Available
Rash23.03.13.001--Not Available
Shock24.06.02.002--Not Available
Sleep disorder19.02.04.001--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages